ARCHIVES

Varmus: NCI Needs To Rethink, Review; Programs Must Be “At A High Level”

This article is from The Cancer Letter archive.

Vol. 36 No. 41 | November 12, 2010

Download PDF Visit The Full Archive

Related Articles

FDA Declares Taxol Orphan Drug For KS; Can IVAX Break Bristol’s Exclusivity?

August 15, 1997

Cancer Informatics: NCI Writing Dictionary To Standardize Data Reported In Trials

November 13, 1998

NTP Board Approves Concept Of Human Cell Assay For Genetic Toxicity

March 25, 1983

In Brief: NCI Scientist Accused Of Taking ‘Payoffs’ Forom Drug Firms; GM-CS Wins FDA Approval

March 15, 1991

PDF file includes 8-page February issue of Business & Regulatory Report.

February 27, 2004

Mass. ACS Offers Three Programs For Young Investigators

July 24, 1987